Research - Eloxx (ELOX) is developing a cystic fibrosis treatment for the 12% of patients that Vertex’s therapies cannot treat. The mechanism of action in the ribosome … Continue Reading
Premium: Read NowResearch - Novavax (NVAX) reported Q1 earnings yesterday after market and it was an overall disappointing update. The company was burdened with delays on all fronts, including US Phase … Continue Reading
Premium: Read NowResearch - The ASCO 2021 meeting is going to be June 4-8. This morning, ASCO 2021 abstract titles were released. May 19th is when selected abstracts (details other than just … Continue Reading
Premium: Read NowResearch - Novavax (NVAX) has been one of the companies most affected by the March biotech decline. It is now trading under $200/share, near levels where it … Continue Reading
Premium: Read NowResearch - Delcath (DCTH) released preliminary data for their Phase 3 in metastatic ocular melanoma (mOM). The preliminary analysis included 79 of 91 (87%) treated patients. Final results on … Continue Reading
Premium: Read NowResearch - 9 Meters (NMTR) is developing a novel treatment for short bowel syndrome (“SBS”) by focusing on slowing food transit time through the gastrointestinal (“GI”) tract. … Continue Reading
Premium: Read NowResearch - Nine Meters Biopharma (NMTR) NMTR has reported top-line Phase 1b/2a data for Short Bowel Syndrome (“SBS”). The gastrointestinal (“GI”) tract is the tract from the mouth to the … Continue Reading
Premium: Read Now
